Operating
Amortization of Investment Discount and Premium
Neurocrine Biosciences Amortization of Investment Discount and Premium decreased by 35.0% to $1.3M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 71.7%, from $4.6M to $1.3M. Over 4 years (FY 2021 to FY 2025), Amortization of Investment Discount and Premium shows an upward trend with a 14.5% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
Fluctuations reflect changes in the interest rate environment and the company's treasury management strategy.
Detailed definition
This represents the non-cash adjustment for the accretion of discounts or amortization of premiums on marketable debt se...
Peer comparison
Common for companies with large cash balances and significant investment portfolios.
Metric ID:
anet_investment_income_amortizationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$1.85M | -$1.85M | -$1.85M | -$925K | -$925K | -$925K | -$925K | $2.1M | $3.9M | $6M | $6.3M | $7.1M | $7M | $6.5M | $5.6M | $4.6M | $3.4M | $2.7M | $2M | $1.3M |
| QoQ Change | — | +0.0% | +0.0% | +50.0% | +0.0% | +0.0% | +0.0% | +327.0% | +85.7% | +53.8% | +5.0% | +12.7% | -1.4% | -7.1% | -13.8% | -17.9% | -26.1% | -20.6% | -25.9% | -35.0% |
| YoY Change | — | — | — | — | +50.0% | +50.0% | +50.0% | +327.0% | +521.6% | +748.6% | +781.1% | +238.1% | +79.5% | +8.3% | -11.1% | -35.2% | -51.4% | -58.5% | -64.3% | -71.7% |
Range-$1.85M – $7.1M
CAGR-7.2%
Avg YoY Growth+160.1%
Median YoY Growth+50.0%
Current Streak8 quarters decline
Amortization of Investment Discount and Premium at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's amortization of investment discount and premium?
- Neurocrine Biosciences (NBIX) reported amortization of investment discount and premium of $1.3M in Q1 2026.
- How has Neurocrine Biosciences's amortization of investment discount and premium changed year-over-year?
- Neurocrine Biosciences's amortization of investment discount and premium decreased by 71.7% year-over-year, from $4.6M to $1.3M.
- What is the long-term trend for Neurocrine Biosciences's amortization of investment discount and premium?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's amortization of investment discount and premium has grown at a 14.5% compound annual growth rate (CAGR), from -$7.4M to $12.7M.
- What does amortization of investment discount and premium mean?
- Non-cash adjustments to the value of investment holdings due to interest rate or market price changes.